Skip to main content

Research Interests


Dr. Green’s research has focused primarily upon strategies to predict, prevent, and treat diabetes mellitus.  In particular, she is interested in the effects of various interventions to modify glycemic control, dyslipidemia, and hypertension upon cardiovascular and other diabetes-related complications.  She has served as an investigator in federally funded clinical trials of type 2 diabetes management including ACCORD, BARI 2D, and GRADE, and is a member of the data and safety monitoring board for the NIDDK consortium of artificial pancreas studies. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, Harmony Outcomes).  She has recently been appointed PI of the US Coordinating Center for EMPA-KIDNEY: A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease. Dr. Green also leads a study team within the DCRI and Duke Data Science groups focused upon utilization of electronic health data to guide and improve medical decision-making in the care of patients with diabetes.

A full listing of publications to which I have contributed can be found here:

https://www.ncbi.nlm.nih.gov/sites/myncbi/1N3tmspW86aAM/bibliography/47644101/public/?sort=date&direction=descending

Selected Grants


EASi-KIDNEY: The Study of Heart and Kidney Protection with "BI 690517"

Clinical TrialPrincipal Investigator · Awarded by The Chancellor Masters and Scholars of the University of Oxford · 2023 - 2029

MASTER

Clinical TrialPrincipal Investigator · Awarded by Bluedrop RPM, Inc. · 2023 - 2025

EMPA-KIDNEY Trial

Clinical TrialPrincipal Investigator · Awarded by The Chancellor Masters and Scholars of the University of Oxford · 2018 - 2025

Endocrinology and Metabolism Training Program (Summer 2024)

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1975 - 2024

EASi-KIDNEY: The Study of Heart and Kidney Protection with "BI 690517"

Clinical TrialPrincipal Investigator · Awarded by The Chancellor Masters and Scholars of the University of Oxford · 2023 - 2029

MASTER

Clinical TrialPrincipal Investigator · Awarded by Bluedrop RPM, Inc. · 2023 - 2025

EMPA-KIDNEY Trial

Clinical TrialPrincipal Investigator · Awarded by The Chancellor Masters and Scholars of the University of Oxford · 2018 - 2025

Endocrinology and Metabolism Training Program (Summer 2024)

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 1975 - 2024

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) - Microbiome Collection

Clinical TrialPrincipal Investigator · Awarded by The George Washington University · 2012 - 2023

Roche Diabetes Care_LOI

ResearchPrincipal Investigator · Awarded by Roche Diagnostics · 2020 - 2023

Hostility, PTSD and Physical Health Risk Factors

ResearchCo Investigator · Awarded by National Institutes of Health · 2009 - 2015

Fellowships, Gifts, and Supported Research


EMPA-KIDNEY. A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease · 2017 Principal Investigator, US Coordinating Center · Boehringer Ingelheim/University of Oxford
Predictive Algorithm and Reinforcement Learning for Diabetes Management: (PEARL-DM) · 2017 Clinical Principal Investigator · DCRI Innovation Grant/Duke Forge
Consolidated Sotagliflozin Study Program (SOTA) Non-CV Outcomes · 2017 Principal Investigator: Clinical Events Adjudication Committee (non-CV events) · Sanofi
Advanced Clinical Trials to Test Artificial Pancreas (AP) Device Systems in Type 1 Diabetes (UC4). NIDDK Cooperative Agreement · 2016 Data and Safety Monitoring Board Member · NIDDK
TECOS: A Phase III, Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus · 2008 Investigator and Clinical Lead: Duke Clinical Research Institute Co-Chair: TECOS Operations Committee Chair: TECOS Clinical Events Committee · Merck
EMPA-KIDNEY. A Multicentre International Randomized Parallel Group Double-Blind Placebo-Controlled Clinical Trial of Empagliflozin Once Daily To Assess Cardio-Renal Outcomes in Patients With Chronic Kidney Disease · 2017 Principal Investigator, US Coordinating Center · Boehringer Ingelheim/University of Oxford
Predictive Algorithm and Reinforcement Learning for Diabetes Management: (PEARL-DM) · 2017 Clinical Principal Investigator · DCRI Innovation Grant/Duke Forge
Consolidated Sotagliflozin Study Program (SOTA) Non-CV Outcomes · 2017 Principal Investigator: Clinical Events Adjudication Committee (non-CV events) · Sanofi
Advanced Clinical Trials to Test Artificial Pancreas (AP) Device Systems in Type 1 Diabetes (UC4). NIDDK Cooperative Agreement · 2016 Data and Safety Monitoring Board Member · NIDDK
TECOS: A Phase III, Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus · 2008 Investigator and Clinical Lead: Duke Clinical Research Institute Co-Chair: TECOS Operations Committee Chair: TECOS Clinical Events Committee · Merck
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Duke University Medical Center, Durham, North Carolina · 2012 NIDDK
The EXSCEL Trial. A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus · 2009 Chair, Clinical Events Classification Committee: · AstraZeneca/BMS
COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs). Duke Clinical Research Institute, Duke University Medical Center · 2018 Boehringer Ingelheim
American Heart Association (AHA) SFRN/Duke Clinical Research Institute Heart failure Center. Project: Improving Population Health for Patients with Diabetes and Heart Failure. Duke University Medical Center, Durham, North Carolina · 2016 AHA
Vitamin D and Type 2 Diabetes Study (D2d) · 2013 Co-investigator · NIDDK
Albiglutide Phase IV HARMONY Outcomes Trial Protocol GLP116174 · 2015 DCRI Clinical Lead · GSK

External Relationships


  • Academy for Continued Healthcare Learning
  • American Board of Internal Medicine
  • American Diabetes Association
  • Anji
  • Bayer Healthcare Pharmaceuticals
  • Academy for Continued Healthcare Learning
  • American Board of Internal Medicine
  • American Diabetes Association
  • Anji
  • Bayer Healthcare Pharmaceuticals
  • Boehringer Ingelheim
  • CEA Group
  • Cardiovascular Institute of Philadelphia
  • Continuing Education Company
  • Eli Lilly & Co.
  • Encore Medical Education
  • Horizon CME/Pri-Med
  • Institute for Medical and Nursing Education
  • Kaplan, Inc
  • MJH Life Sciences
  • Merck
  • Metabolic Institute of America
  • Novo Nordisk
  • The Cleveland Clinic Foundation
  • The Endocrine Society
  • University of Texas Health Science Center
  • Valo Health
  • Vertex Pharmaceuticals Inc.
  • WebMD

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.